{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Number of participants with an anti-lymphoma effect, defined as any reduction during the course of study in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by computed tomography scan as assessed by an independent review committee; lymphadenopathy is defined as any node with longest diameter (LDi) \\> 1.5 cm and splenomegaly is defined as vertical spleen length \\> 13 cm","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy Analysis Set includes participants with confirmed Waldenström's macroglobulinemia based on central pathologic review among those who received at least one dose of study drug and with a baseline IgM (or M-protein) ≥ 5 g/L","reportingStatus":"POSTED","timeFrame":"Up to approximately 1 year and 9 months","title":"Number of Participants With an Anti-lymphoma Effect","type":"SECONDARY","unitOfMeasure":"Participants"}